Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
VE1-H82E7 | Human | Biotinylated Human VEGF121 Protein, Avitag™,His Tag | ![]() |
![]() ![]() |
![]() ![]() |
VE1-H5246 | Human | Human VEGF121 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
VE1-H4213 | Human | ActiveMax® Human VEGF121 Protein, Tag Free | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
Immobilized Human VEGF121, His Tag (Cat. No. VE1-H5246) at 1 μg/mL (100 μL/well) can bind Human VEGFR1/R2, Fc Tag with a linear range of 0.4-6 ng/mL (QC tested).
The purity of Human VEGF121, His Tag (Cat. No. VE1-H5246) is more than 90% and the molecular weight of this protein is around 36-46 kDa verified by SEC-MALS.
Immobilized Human VEGF121, His Tag (Cat. No. VE1-H5246) at 1 μg/mL (100 μL/well) can bind Human VEGFR1/R2, Fc Tag with a linear range of 0.4-6 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Bevacizumab biosimilar (Hetero Drugs) | Approved | Hetero Drugs | Cizumab | India | Colorectal Neoplasms | Hetero Drugs | 2016-01-01 | Colorectal Neoplasms | Details | |
Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | Japan | Colorectal Neoplasms | Sanofi | 2012-08-03 | Ovarian Neoplasms; Solid tumours; Ascites; Lung Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis | Details |
Bevacizumab biosimilar (Boan Biopharma) | LY-01008 | Approved | Shandong Boan Biotechnology Co Ltd | 博优诺 | Mainland China | Carcinoma, Hepatocellular | Shandong Boan Biotechnology Co Ltd | 2021-05-07 | Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Bevacizumab biosimilar (Zydus Cadila) | Approved | Zydus Cadila | Bryxta | India | Carcinoma, Non-Small-Cell Lung | Zydus Cadila | 2017-01-01 | Carcinoma, Non-Small-Cell Lung | Details | |
Bevacizumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr. Reddy’S Laboratories Ltd | Versavo | India | Glioma; Carcinoma, Renal Cell; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Dr. Reddy’S Laboratories Ltd | 2019-01-01 | Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Glioma; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
Ranibizumab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Razumab | India | Macular Degeneration | Intas Biopharmaceuticals | 2015-01-01 | Macular Degeneration | Details | |
Bevacizumab Biosimilar (AXXO) | Approved | Axxo | Russian Federation | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Axxo | 2013-01-01 | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | ||
Bevacizumab biosimilar (Elea) | Approved | Elea | Lumiere | Argentina | Macular Degeneration | Elea | 2018-09-01 | Macular Degeneration | Details | |
Neovasculgen | PI-VEGF165 | Approved | Human Stem Cells Institute | Neovasculgen | Russian Federation | Peripheral Arterial Disease | Human Stem Cells Institute | 2011-12-07 | Peripheral Arterial Disease | Details |
Bevacizumab biosimilar (Biocad) | BCD-021 | Approved | Biocad | Avegra | Russian Federation | Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Biocad | 2015-11-25 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Conbercept | FP-3; KH-902 | Approved | Chengdu Kanghong Biotechnologies Co Ltd | 朗沐, Langmu | Mainland China | Macular Degeneration | Chengdu Kanghong Biotechnologies Co Ltd | 2013-11-27 | Macular Edema; Vision Disorders; Wet Macular Degeneration; Diabetic macular oedema; Retinoblastoma; Corneal Neovascularization; Macular Degeneration; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetes Mellitus | Details |
Bevacizumab biosimilar (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Bevatas | Carcinoma, Non-Small-Cell Lung | Details | |||||
Bevacizumab biosimilar (Biocon/Mylan) | MYL-1402O | Approved | Biocon | KRABEVA | EU | Carcinoma, Renal Cell; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Mylan Ire Healthcare Ltd | 2017-01-01 | Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Brain Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Ranibizumab biosimilar (Samsung Bioepis) | SB-11 | Approved | Samsung Bioepis | BYOOVIZ | United States | Macular Degeneration; Macular Edema; Choroidal Neovascularization | null, Samsung Bioepis Co Ltd | 2021-08-18 | Macular Edema; Wet Macular Degeneration; Macular Degeneration; Choroidal Neovascularization; Diabetic Retinopathy | Details |
Bevacizumab biosimilar (Innovent Biologics) | IBI-305; IBI305; IBI 305 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达攸同, BYVASDA | Mainland China | Carcinoma, Hepatocellular | Innovent Biologics(Suzhou) Co Ltd | 2020-06-17 | Glioblastoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (Jiangsu Hengrui Medicine) | BP-102 | Approved | Jiangsu Hengrui Medicine Co Ltd | Mainland China | Rectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2021-06-22 | Solid tumours; Rectal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
Bevacizumab biosimilar (Betta/Mabworks) | MIL-60 | Approved | Institute Of Basic Medicine, Chinese Academy Of Medical Sciences, Beijing Mabworks Biotech Co Ltd | 贝安汀 | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Betta Pharmaceuticals Co Ltd | 2021-11-24 | Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
Bevacizumab biosimilar (TOT Biopharm) | TAB-008; TOT-102; TAB008; TOT102 | Approved | Tot Biopharm Co Ltd | 朴欣汀, Pusintin | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Tot Biopharm Co Ltd | 2021-12-01 | Glioblastoma; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Aflibercept | BAT-86-5321; BAY-865321 | Approved | Regeneron Pharmaceuticals Inc, Bayer Ag | Eylea | Mainland China | Macular Degeneration; Macular Edema | Bayer Australia Ltd | 2011-11-18 | Diabetes Complications; Neoplasm Metastasis; Retinopathy of Prematurity; Retinal Vein Occlusion; Macular Degeneration; Diabetic Retinopathy; Diabetes Mellitus; Retinal Degeneration; Colorectal Neoplasms; Diabetes Mellitus, Type 1; Prostatic Neoplasms; Wet Macular Degeneration; Diabetic macular oedema; Myopia, Degenerative; Retinal Diseases; Glaucoma, Neovascular; Diabetes Mellitus, Type 2; Macular Edema | Details |
Bevacizumab biosimilar (Shanghai Henlius Biotech) | HLX-04; HLX04-O | Approved | Shanghai Henlius Biotech Co Ltd | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Shanghai Henlius Biopharmaceuticals Co Ltd | 2021-11-30 | Solid tumours; Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Macular Degeneration | Details | |
Ranibizumab biosimilar (Senju) | GBS-007; OT-701; SJP-0133 | Approved | Senju Pharmaceutical Co Ltd | Japan | Macular Degeneration | Senju Pharmaceutical Co Ltd | 2021-09-27 | Macular Degeneration | Details | |
Bevacizumab biosimilar (Bio-Thera Solutions) | BAT-1706 | Approved | Bio-Thera Solutions Ltd | 普贝希 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Beigene Ltd, Bio-Thera Solutions Ltd | 2021-11-17 | Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
Ranibizumab | rhuFab-V2; Y-0317; RFB-002; RG-6321; RG-3645; rhu-Fab-VEG; AMD-rhuFab-V2; AMD-Fab | Approved | Novartis Pharma Ag, Genentech Inc | Lucentis, 诺适得, Susvimo | Japan | Diabetic macular oedema | Novartis Pharma Ag | 2006-06-30 | Macular Edema; Vision Disorders; Glaucoma, Neovascular; Neovascularization, Pathologic; Myopia, Degenerative; Retinal Diseases; Diabetic macular oedema; Wet Macular Degeneration; Retinal Degeneration; Macular Degeneration; Choroidal Neovascularization; Diabetic Retinopathy; Retinal Vein Occlusion; Diabetes Mellitus; Myopia; Retinopathy of Prematurity | Details |
Faricimab | RG-7716; RO-6867461 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | Vabysmo | United States | Diabetic macular oedema; Wet Macular Degeneration | Genentech Inc | 2022-01-28 | Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Mellitus; Macular Degeneration; Retinal Vein Occlusion | Details |
Bevacizumab biosimilar (mAbixience) | MB02; BEVZ-92; BEVZ92-MB02 | Approved | Mabxience | Alymsys | EU | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Breast Neoplasms; Uterine Cervical Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms | Stada Arzneimittel Ag, Mabxience Sa | 2013-10-25 | Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar (Allergan/Amgen) | ABP-215 | Approved | Amgen Inc | Mvasi | Japan | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell | Daiichi Sankyo Co Ltd | 2017-09-14 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar (Samsung Bioepis) | SB-8; SP-8 | Approved | Samsung Bioepis | Aybintio | EU | Carcinoma, Ovarian Epithelial; Uterine Cervical Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Carcinoma, Renal Cell | Samsung Bioepis Nl Bv | 2020-08-19 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar (Pfizer) | PF-6439535; PF-06439535 | Approved | Pfizer Inc | Zirabev | United States | Peritoneal Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms | Pfizer Inc | 2019-02-14 | Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Bevacizumab | G180CU; RO-4876646; RG-435; NSC-704865; G180CL; R-435; G180DL | Approved | Genentech Inc | 安维汀, Avastin | Mainland China | Carcinoma, Hepatocellular | Roche Pharmaceutical Co Ltd | 2004-02-26 | Peritoneal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Macular Degeneration; Carcinoma, Hepatocellular; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Glioma; Fallopian Tube Neoplasms; Ovarian Neoplasms; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Breast Neoplasms; Multiple Myeloma; Glioblastoma; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Liver Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
LHA-510 | LHA-510 | Phase 2 Clinical | Alcon | Macular Degeneration | Details |
Ranibizumab biosimilar (Pfenex) | PF-582 | Phase 2 Clinical | Pfenex | Macular Degeneration | Details |
Ranibizumab biosimilar (Shanghai United Cell Biotechnology) | Phase 1 Clinical | Shanghai United Cell Biotechnology Co Ltd | Macular Edema; Macular Degeneration | Details | |
LMG-324 | LMG-324 | Phase 2 Clinical | Alcon | Macular Degeneration | Details |
Bevacizumab biosimilar (Celltrion) | CT-16; CTP-16 | Phase 3 Clinical | Celltrion | Adenocarcinoma of Lung; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (AryoGen Biopharma) | Phase 3 Clinical | Aryogen Biopharma | Colorectal Neoplasms | Details | |
Ranibizumab biosimilar (CJSC Generium) | GNR-067 | Phase 1 Clinical | Cjsc Generium | Macular Degeneration | Details |
Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Macular Degeneration | Details |
Aflibercept Biosimilar (Clover Biopharmaceuticals) | SCB-420 | Phase 1 Clinical | Sichuan Sanyecao Bio-Pharmaceutical Co Ltd | Diabetic macular oedema; Macular Degeneration | Details |
CLS-1002 | CLS-1002 | Phase 1 Clinical | Clearside Biomedical | Macular Degeneration | Details |
Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Phase 3 Clinical | Mylan, Momenta | Diabetic macular oedema | Details |
Bevacizumab biosimilar (Alphamab/R-Pharm) | RPH-001 | Phase 3 Clinical | Suzhou Alphamab Co Ltd, R-Pharm | Colorectal Neoplasms | Details |
Bevacizumab biosimilar (Tanvex BioPharma) | TX-16 | Phase 1 Clinical | Tanvex Biopharma | Colorectal Neoplasms | Details |
Aflibercept biosimilar (CinnaGen)(阿柏西普生物类似药(CinnaGen)) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
Ranibizumab biosimilar (Lupin) | LUBT-010 | Phase 3 Clinical | Rubin Ltd | Macular Degeneration | Details |
Bevacizumab biosimilar (Eastern Biotech) | JY-028 | Phase 1 Clinical | Beijing Eastern Biotech Co Ltd | Wet Macular Degeneration; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (JHL Biotech) | JHL-1149 | Phase 1 Clinical | JHL Biotech | Ovarian Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) | Phase 1 Clinical | Pepscan Systems | Colorectal Neoplasms | Details | |
Aflibercept Biosimilar (Boan Biopharma/Luye Pharma) | LY-09004; BA-9101; OT-702 | Phase 3 Clinical | Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
Bevacizumab biosimilar (Synermore Biologics) | SYN-050 | Phase 1 Clinical | Lonn Ryonn Pharma Ltd | Neoplasms | Details |
Bevacizumab biosimilar (Hualan Biological Engineering) | WBP-264 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Muparfostat sodium | PI-88 | Phase 3 Clinical | Australian National University | Liver Neoplasms; Solid tumours; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Ranibizumab biosimilar (Qilu Pharmaceutical) | BCD-300; QL-1205 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd, Biocnd | Wet Macular Degeneration; Macular Degeneration | Details |
Ranibizumab biosimilar (Reliance Life Sciences Group) | R-TPR-024 | Phase 3 Clinical | Reliance Life Sciences | Macular Degeneration | Details |
Vanucizumab | RG-7221; RO-5520985; B800Z06O8K (UNII code) | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
OB-318 | OB-318 | Phase 1 Clinical | Oneness Biotech | Solid tumours; Carcinoma, Hepatocellular | Details |
SCT-501(National Cancer Institute) | SCT-501 | Phase 2 Clinical | National Cancer Institute | Kidney Neoplasms | Details |
Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Colorectal Neoplasms | Details |
Bevacizumab biosimilar (Gedeon Richter) | Phase 1 Clinical | Gedeon Richter Plc | Neoplasms | Details | |
CT-P42 | CT-P42 | Phase 3 Clinical | Celltrion | Diabetic macular oedema | Details |
Bevacizumab biosimilar (CTTQ Pharma) | TQ-B2302 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Ovarian Neoplasms; Glioblastoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
MP-0250 | MP-0250 | Phase 2 Clinical | Molecular Partners | Neoplasms; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) | HD-204 | Phase 3 Clinical | Hanwha Biologics | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Ranibizumab biosimilar (Xbrane) | Phase 3 Clinical | Xbrane Biopharma | Macular Degeneration | Details | |
ALS-L1023 | ALS-L1023 | Phase 2 Clinical | Angiolab Inc | Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Obesity; Macular Degeneration | Details |
Aflibercept/Nesvacumab | REGN 910-3 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Diabetic macular oedema; Macular Degeneration | Details |
AZD-8601 | mRNA-AZD-8601; AZD-8601 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Heart Failure | Details |
Varisacumab | R-84; GNR-011; AT-001-IBCG | Phase 3 Clinical | Peregrine, Ut Southwestern Medical Center | Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (Reliance Life Sciences) | R-TPR-023 | Phase 3 Clinical | Reliance Life Sciences | Colorectal Neoplasms | Details |
Intravitreal ranibizumab (Sultan Qaboos University) | Phase 2 Clinical | Sultan Qaboos University | Retinal Dysplasia | Details | |
Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 2 Clinical | Abbvie Inc | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
BI-695502 | BI-695502 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Brain Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (Cipla BioTec) | CBT-124 | Phase 3 Clinical | Cipla Gmbh | Carcinoma, Non-Small-Cell Lung | Details |
FYB-203 | FYB-203 | Phase 3 Clinical | Formycon | Macular Degeneration | Details |
Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical) | CKD-701 | Phase 3 Clinical | Chong Kun Dang Pharmaceutical Corp | Macular Degeneration | Details |
Bevacizumab biosimilar (Oncobiologics) | ONS-1045; ONS-5010 | Phase 3 Clinical | Outlook Therapeutics | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Retinal Vein Occlusion | Details |
Recombinant anti-VEGF humanized monoclonal antibody (Jiangsu Aosaikang Pharmaceutical) | ASK-1202; AMD-B; AK-3008 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Diabetic macular oedema; Macular Degeneration | Details |
Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
Aflibercept Biosimilar(Alvotech Swiss) | AVT-06 | Phase 3 Clinical | Alvotech Swiss Ag | Macular Degeneration | Details |
Bevacizumab biosimilar (Centus Biotherapeutics) | FKB-238 | Phase 3 Clinical | Fujifilm Kyowa Kirin Biologics Co Ltd | Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Aflibercept biosimilar (Amgen) | ABP-938 | Phase 2 Clinical | Amgen Inc | Macular Degeneration | Details |
Aflibercept biosimilar (Samsung Bioepis) | SB-15 | Phase 3 Clinical | Samsung Bioepis | Macular Degeneration | Details |
Eylea Biosimilar (Alteogen) | ALT-L9 | Phase 1 Clinical | Alteogen Inc, Kissei Pharmaceutical | Macular Degeneration | Details |
TR-009 | NOV-1501; ABL001-ABL Bio; ABL-001-ABL Bio; ES-104; CTX-009 | Phase 2 Clinical | Abl Bio | Solid tumours; Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms | Details |
RC-28 | RC28-E; RC-28-E; RC-28 | Phase 2 Clinical | RemeGen Co Ltd | Wet Macular Degeneration; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration | Details |
ASC-06 | ALN-VSP; ALN-VSP01; ALN-VSP02; ASC-06 | Phase 1 Clinical | Alnylam Pharmaceuticals Inc | Solid tumours; Liver Neoplasms | Details |
Bevacizumab (Beijing Science Sun) | K-11; K11 | Phase 3 Clinical | Beijing Science Sun Pharmaceutical Co Ltd | Glioblastoma; Neoplasms; Diabetic macular oedema; Glioma; Carcinoma, Hepatocellular | Details |
Emvododstat | PTC-299 | Phase 3 Clinical | Ptc Therapeutics Inc | Pneumonia; Esophageal Neoplasms; Neurofibromatosis 2; Coronavirus Disease 2019 (COVID-19); Neurofibromatoses; Breast Neoplasms; Coronavirus Infections; Leukemia, Myeloid, Acute; Sarcoma, Kaposi | Details |
ASKG-712 | ASKG712 | Phase 1 Clinical | Suzhou aosaikang biomedical Co Ltd | Wet Macular Degeneration | Details |
BI-836880 | BI-836880 | Phase 2 Clinical | Ablynx | Wet Macular Degeneration; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
Sevacizumab | 9MW0211; 9MW-0211; SIM-BD-0801; EPI-0030; BD-0801; TK-001; APX-003 | Phase 3 Clinical | Epitomics | Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Wet Macular Degeneration; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration | Details |
This web search service is supported by Google Inc.